15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 18 firms covering Abbott Laboratories, 18 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $112.00 to $146.00, so the covering firms are broadly aligned. The average target of $123.06 sits 15% above the current $107.36. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 16 to 18 over recent months. On the fundamentals, the Street sees revenue growth near 13% this year and 9% next, consensus EPS building from about $1.64 next quarter toward $6.06 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS18 ratings
Moderate Buy
Strong Buy00%
Buy18100%
Hold00%
Sell00%
Strong Sell00%
Based on 18 analysts giving stock ratings to Abbott Laboratories.
As of Jul, 18 of 18 firms rate ABT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ABT EPS & revenue forecast
EPS · NEXT QUARTER
$1.64
Range $1.59 – $1.66 · 22 analysts · +9% YoY
Next period, 22 analysts expect Abbott Laboratories to earn $1.64 a share (range $1.59 – $1.66), versus $1.50 a year earlier. Full-year consensus is $5.51, growing to $6.06 the year after.
REVENUE · NEXT QUARTER
$13.5B
Range $13.3B – $13.7B · 22 analysts · +16% YoY
Revenue is expected to reach $13.5B (range $13.3B – $13.7B), +16.0% year-over-year. Full-year consensus is $50.3B, rising to $54.6B next year.
Top analysts covering Abbott Laboratories
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ABT.
#1
Bruce Jackson
Benchmark · Rank #317
Buy
$120.00+11.8% to target
Overall win rate
35%
+ Follow
#2
MT
Marie Thibault
BTIG
Buy
$134.00+24.8% to target
Coverage
—
+ Follow
#3
Vijay Kumar
Evercore ISI Group
Buy
$120.00+11.8% to target
Coverage
—
+ Follow
#4
Matt Miksic
Barclays
Buy
$143.00+33.2% to target
Coverage
—
+ Follow
#5
Adam Maeder
Piper Sandler
Buy
$118.00+9.9% to target
Coverage
—
+ Follow
ABT stock forecast FAQ
What is ABT's average 12-month price target?+
The 17 analysts with a live target average $123.06 for Abbott Laboratories over the next 12 months, ranging from a $146.00 high to a $112.00 low.
Is ABT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 18 analyst ratings, 18 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ABT?+
The Street-high target is $146.00 (Raymond James), and the Street-low is $112.00 (Citigroup). The average of all 17 active targets is $123.06.
How many Wall Street analysts cover ABT?+
18 analysts have an active rating on Abbott Laboratories, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering ABT?+
Among analysts who currently cover ABT, Bruce Jackson of Benchmark has the strongest overall Quantellect track record (Rank #317). Their current call is Buy with a $120.00 target.
What is Abbott Laboratories's projected EPS for next quarter?+
The consensus estimate is $1.64 per share (range $1.59 – $1.66) across 22 analysts. Full-year EPS is projected at $5.51, rising to $6.06 the following year.
How much revenue is Abbott Laboratories expected to report next quarter?+
Consensus revenue is $13.5B (range $13.3B – $13.7B). Full-year revenue is projected at $50.3B, growing to $54.6B next year.
Have analysts been upgrading or downgrading ABT lately?+
As of Jul, 18 of 18 firms rate ABT a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ABT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
